Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VIP152 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose escalation of VIP152 (BAY 1251152) / PART 1 (Completed) | EXPERIMENTAL | Investigating VIP152 (BAY 1251152) in a dose escalation cohort in patients with solid tumors and aggressive NHL |
| Dose expansion of VIP152 (BAY 1251152) / PART 2 | EXPERIMENTAL | Investigating VIP152 (BAY 1251152) in a dose expansion cohort in patients with solid tumors and aggressive NHL |
| Dose escalation of VIP152 (BAY 1251152) in combination with Keytruda® (pembrolizumab) / PART 3 | EXPERIMENTAL | Investigating combination VIP152 (BAY 1251152) and Keytruda® (pembrolizumab) in a dose escalation cohort in patients with advanced cancer. All subjects must be eligible to use pembrolizumab per USPI. |
| Dose expansion of VIP152 (BAY 1251152) in combination with Keytruda® (pembrolizumab) / PART 4 | EXPERIMENTAL | Investigating combination VIP152 (BAY 1251152) and Keytruda® (pembrolizumab) in a dose expansion cohort in patients with advanced cancer. All subjects must be eligible to use pembrolizumab per USPI. |
| Name | Type | Description |
|---|---|---|
| VIP152 (BAY 1251152) | DRUG | The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles. |
| VIP152 (BAY 1251152) 30 mg | DRUG | 30 mg IV (30 minute infusion) fixed dose once weekly of a 21 day cycle. |
| Keytruda | DRUG | 200 mg IV fixed dose once every 3 weeks of a 21 day cycle |
| VIP152 (BAY 1251152) 15 mg | DRUG | The starting dose of Cohort 3 will be 15 mg IV (30 minute infusion) fixed dose once weekly (15 mg/week) for 21 day cycles. |
Part 2 (Global), Part 3 (US Only), and Part 4 (US Only) Inclusion Criteria: * Male or female patients aged \>/=18 years * Patients with a histologically or cytologically confirmed solid tumor or aggressive NHL who are refractory to or have exhausted all available therapies with MYC expression or k...
VIP152 is an investigational small molecule being developed for the treatment of neoplasms, which are abnormal growths of tissue that can be cancerous. It is currently in clinical development for oncology indications, specifically targeting advanced cancer in patients.
VIP152 is being developed by Vincerx Pharma, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VINC. The company is focused on advancing this oncology therapy through clinical development.
VIP152 is in Phase 1 clinical development. It has completed a Phase 1 dose escalation study in patients with advanced cancer. As an investigational drug, it is not yet approved by regulatory authorities and remains in clinical trials.
VIP152 has been studied in a Phase 1 dose escalation trial with the identifier NCT02635672. This completed trial enrolled 110 participants with neoplasms across the United States, Chile, and Spain, and included adult patients of all sexes.
VIP152 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. Further clinical development and regulatory review would be required before it could be considered for approval.